2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Future Oncology FUTURE ONCOL (此期刊被最新的JCR期刊SCIE收录) LetPub评分 6.6
52人评分
我要评分
声誉 7.6 影响力 5.2 速度 9.1 | |||||||||||||||||||||
期刊ISSN | 1479-6694 | 微信扫码收藏此期刊 | ||||||||||||||||||||
E-ISSN | 1744-8301 | |||||||||||||||||||||
2023-2024最新影响因子 (数据来源于搜索引擎) | 3 点击查看影响因子趋势图 | |||||||||||||||||||||
实时影响因子 | 截止2024年3月26日:2.899 | |||||||||||||||||||||
2023-2024自引率 | 3.30%点击查看自引率趋势图 | |||||||||||||||||||||
五年影响因子 | 2.9 | |||||||||||||||||||||
JCI期刊引文指标 | 0.61 | |||||||||||||||||||||
h-index | 60 | |||||||||||||||||||||
CiteScore ( 2024年最新版) |
| |||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||
期刊官方网站 | http://www.futuremedicine.com/loi/fon | |||||||||||||||||||||
期刊投稿网址 | http://www.futuremedicine.com/page/submitarticle | |||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Future Oncology的语言要求,还能让Future Oncology编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Future Oncology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(1篇) 。
提交文稿 | |||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||
通讯方式 | FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB | |||||||||||||||||||||
出版商 | Future Medicine Ltd. | |||||||||||||||||||||
涉及的研究方向 | ONCOLOGY- | |||||||||||||||||||||
出版国家或地区 | ENGLAND | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | Monthly | |||||||||||||||||||||
出版年份 | 2005 | |||||||||||||||||||||
年文章数 | 261点击查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 44.63% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 79.31% | |||||||||||||||||||||
WOS期刊SCI分区 ( 2023-2024年最新版) | WOS分区等级:2区
| |||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月升级版) |
| |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2021年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1479-6694%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: 偏慢,4-8周 | |||||||||||||||||||||
平均录用比例 | 网友分享经验: | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Future Oncology顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
|
中国学者近期发表的论文 | |
1. | Value of biomarkers in epithelial-mesenchymal transition models of liver cancer under different interventions: a meta-analysis Author: Yan, Jing; Xie, Bei; Zou, Shuli; Huang, Li; Tian, Ye; Li, Jing; Peng, Zhiheng; Liu, Zhuan; Ma, Bin; Li, Linjing Journal: FUTURE ONCOLOGY. 2023; Vol. 18, Issue 36, pp. 4031-4045. DOI: 10.2217/fon-2022-0344 PubMed DOI |
2. | The roles of IDH1 in tumor metabolism and immunity Author: Ni, Yingqian; Shen, Peibo; Wang, Xingchen; Liu, He; Luo, Huiyuan; Han, Xiuzhen Journal: FUTURE ONCOLOGY. 2023; Vol. 18, Issue 35, pp. 3941-3953. DOI: 10.2217/fon-2022-0583 PubMed DOI |
3. | Preoperative assessment of high-grade endometrial cancer using a radiomic signature and clinical indicators Author: Zheng, Tao; Pan, Jiangyang; Du, Dan; Liang, Xin; Yi, Huiling; Du, Juan; Wu, Shuo; Liu, Lanxiang; Shi, Gaofeng Journal: FUTURE ONCOLOGY. 2023; Vol. 19, Issue 8, pp. 587-601. DOI: 10.2217/fon-2022-0631 PubMed DOI |
4. | A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial Author: Lu, Sheng; Chen, Yi-Gang; Liu, Xiao-Wen; Yang, Zhong-Yin; Shi, Min; Yuan, Hong; Liu, Wen-Tao; Ni, Zhen-Tian; Yao, Xue-Xin; Hua, Zi-Chen; Feng, Run-Hua; He, Chang-Yu; Zheng, Ya-Nan; Wang, Zhen-Qiang; Sah, Birendra Kumar; Chen, Ming-Min; Zhu, Zheng-Lun; Li, Chen; Zhang, Jun; Yan, Min; Xia, Jia-Zeng; Zhu, Zheng-Gang; Yan, Chao Journal: FUTURE ONCOLOGY. 2023; Vol. 18, Issue 39, pp. 4239-4249. DOI: 10.2217/fon-2022-0718 PubMed DOI |
5. | Receptor discordance among primary tumors, brain metastases and extra-brain metastases in patients with breast cancer Author: Wang, Qian; Guo, Zhoubo; Huang, Zhou; Sun, Huiru; Zhu, Jingyang; Shi, Jinyan; Zhang, Wencheng; Li, Desheng; Sun, Bing Journal: FUTURE ONCOLOGY. 2023; Vol. 18, Issue 37, pp. 4101-4110. DOI: 10.2217/fon-2022-0498 PubMed DOI |
6. | Psychological distress as risk factor for the efficacy of whole-brain radiotherapy in brain metastasis patients Author: Li, Wen; Gan, Chen; Zuo, He; Yin, Xiangxiang; Jing, Yanyan; Pang, Lulian; Yu, Sheng; Tang, Lingxue; Yao, Senbang; Cheng, Huaidong Journal: FUTURE ONCOLOGY. 2023; Vol. 19, Issue 1, pp. 49-60. DOI: 10.2217/fon-2022-0690 PubMed DOI |
7. | Nomogram to predict overall survival in patients with primary bladder neuroendocrine carcinoma: a population-based study Author: Li, Sheng; Liu, Xiaoqiang; Liu, Weipeng; Fu, Bin Journal: FUTURE ONCOLOGY. 2023; Vol. 18, Issue 38, pp. 4171-4181. DOI: 10.2217/fon-2022-0843 PubMed DOI |
8. | Esophageal stenosis as an independent factor of poor prognosis in patients with ESCC treated with definitive chemoradiotherapy Author: Gui, Zhongxuan; Hu, Wenjun; Kong, Qi; Liu, Can; Xu, Yuechen; Wang, Fan Journal: FUTURE ONCOLOGY. 2023; Vol. 18, Issue 38, pp. 4193-4207. DOI: 10.2217/fon-2022-0125 PubMed DOI |
9. | A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data Author: Cheema, Parneet; Cho, Byoung Chul; Freitas, Helano; Provencio, Mariano; Chen, Yuh Min; Kim, Sang-We; Wu, Yi-Long; Passaro, Antonio; Martin, Claudio; Tiseo, Marcello; Chang, Gee-Chen; Park, Keunchil; Solomon, Benjamin; Burghuber, Otto; Laskin, Janessa; Wang, Ziping; Lee, Sung Yong; Hu, Yanping; Vansteenkiste, Johan; Zhang, He-long; Hanrahan, Emer; Geldart, Thomas; Taylor, Rosemary; Servidio, Leslie; Li, Jingyi; de Marinis, Filippo Journal: FUTURE ONCOLOGY. 2023; Vol. 19, Issue 1, pp. 61-75. DOI: 10.2217/fon-2022-0919 PubMed DOI |
10. | KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer Author: Gratzke, Christian; Kwiatkowski, Mariusz; Giorgi, Ugo De; Martins da Trindade, Karine; De Santis, Maria; Armstrong, Andrew J.; Niu, Cuizhen; Liu, Yingjie; Poehlein, Christian Heinrich Journal: FUTURE ONCOLOGY. 2023; Vol. 18, Issue 37, pp. 4079-4087. DOI: 10.2217/fon-2022-0776 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室